Altimmune and the associated logos are trademarks of Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next-generation therapeutics for the treatment of obesity, liver disease, and other metabolic disorders. With a deep understanding of the interplay between adiposity, inflammation, and liver health, Altimmune is advancing innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD)—conditions closely tied to the growing epidemic of obesity and insulin resistance.

At the core of Altimmune’s liver-focused pipeline is pemvidutide, a dual GLP-1/glucagon receptor agonist designed to reduce body weight, improve glycemic control, and decrease liver fat while directly modulating hepatic inflammation and fibrosis. In Phase 2 trials, pemvidutide has demonstrated significant reductions in liver fat content—up to 80% in some patients—along with robust weight loss and favorable effects on cardiometabolic biomarkers.

Altimmune’s therapeutic strategy embraces a multi-dimensional approach to MASH, targeting not only steatosis and inflammation but also the fibrotic progression that defines advanced disease. By addressing upstream drivers of metabolic dysfunction, pemvidutide holds promise as a disease-modifying therapy with the potential to improve long-term liver and cardiovascular outcomes.

With a focused pipeline and compelling clinical data, Altimmune is positioned to become a key player in the evolving MASH treatment landscape. Through the development of safe, effective, and scalable metabolic therapies, the company aims to offer new hope to millions living with progressive liver disease and metabolic comorbidities.